Company news

Zelluna ASA news in 2025

Zelluna ASA's news releases, calls and decks from 2025, newest first.

View company

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours

December 17, 2025

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

December 16, 2025

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial

December 12, 2025

Zelluna ASA: Cancellation of subsequent repair offering

December 9, 2025

Zelluna ASA: New share capital registered

December 8, 2025

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer

November 28, 2025

Zelluna ASA: Disclosure of large shareholding

November 27, 2025

Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025

November 4, 2025

Zelluna ASA – Key information relating to subsequent offering

November 3, 2025

Zelluna ASA - Successful private placement and retail offering

November 3, 2025

Zelluna ASA – Contemplates private placement

November 3, 2025

Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update

November 3, 2025

Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK

October 9, 2025

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday 17 September 2025

September 10, 2025

Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update

August 20, 2025

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

August 14, 2025

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program

July 3, 2025

Decks in 2025